The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
- PMID: 27790016
- PMCID: PMC5045104
- DOI: 10.2147/OARRR.S14563
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretation
Abstract
Objective: To determine the impact of tocilizumab on physical function and quality of life in patients diagnosed with rheumatoid arthritis.
Methods: A systematic literature review was performed to select for trials that could be used to examine the impact of tocilizumab on patients in terms of health-related physical function, quality of life, and quality of sleep. By examining background therapy, disease duration, and remission rates, we were able to determine the impact that a dose of tocilizumab has on various patients.
Results: A total of 2617 tocilizumab-treated patients and 1271 controls were available for this study. Tocilizumab improved the Health Assessment Questionnaire Disability Index score statistically in comparison to the controls, with odds ratios from 1.4 to 7.0. Tocilizumab improved the physical function measure substantially more than the minimal clinically important difference (MCID) (5 units) - 8.9 and 9.7 - compared to 4.1 and 5.0 for controls. Seven and nine units of improvement were observed when measuring fatigue in rheumatoid arthritis patients. Using the Epworth Sleepiness Scale, we found that sleep improved (from 7.7 [3.1] to 3.4 [2.2]).
Conclusion: Tocilizumab improves function and quality of life and decreases fatigue in patients with rheumatoid arthritis.
Keywords: quality of life; randomized trials; rheumatoid arthritis; sleep; tocilizumab.
Figures
References
-
- Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–2980. - PubMed
-
- Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatic arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371:987–997. - PubMed
-
- Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ) Clin Exp Rheumatol. 2005;23:S14–S18. - PubMed
-
- Talamo J, Frater A, Gallivan S, Young A. Use of the short form 36 (SF36) for the health status measurement in rheumatoid arthritis. Br J Rheumatol. 1997;36:463–469. - PubMed
-
- Luo N, Chew LH, Fong KY, Koh DR, Ng SC, Yoon KH. Validity and reliability of the EQ-5D self-report questionnaire in Chinese-speaking patients with rheumatic diseases in Singapore. Ann Acad Med Singapore. 2003;32:685–690. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
